147 related articles for article (PubMed ID: 32743467)
1. Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide-based vaccine.
Kurahashi R; Motoshima T; Fukushima Y; Murakami Y; Yatsuda J; Yamaguchi T; Sugiyama Y; Fukushima S; Komohara Y; Suekane S; Kamba T
IJU Case Rep; 2020 Mar; 3(2):44-48. PubMed ID: 32743467
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
3. [Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report].
Sasagawa H; Numakura K; Nakamura G; Kukimoto T; Kikuchi A; Sagehashi R; Yamamoto R; Koizumi A; Nara T; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Habuchi T
Hinyokika Kiyo; 2021 Dec; 67(12):525-528. PubMed ID: 34991292
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
6. [A Case of Myocardial Metastasis of Renal Cell Cancer Treated with Nivolumab].
Asakura T; Nakai Y; Oka T; Okuda Y; Hatano K; Nakayama M; Kakimoto K; Nishimura K
Hinyokika Kiyo; 2020 Jul; 66(7):225-228. PubMed ID: 32723977
[TBL] [Abstract][Full Text] [Related]
7. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
8. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment.
Takayama K; Numakura K; Igarashi R; Habuchi T
IJU Case Rep; 2022 Nov; 5(6):517-520. PubMed ID: 36341192
[TBL] [Abstract][Full Text] [Related]
10. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports.
Takimoto R; Kamigaki T; Gotoda T; Takahashi T; Okada S; Ibe H; Oguma E; Goto S
J Med Case Rep; 2021 Apr; 15(1):191. PubMed ID: 33827668
[TBL] [Abstract][Full Text] [Related]
11. Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma.
Tanriverdi O; Ates S; Sandal KK; Uylas S; Bosna IC; Alkan A
J Oncol Pharm Pract; 2020 Oct; 26(7):1765-1768. PubMed ID: 32164490
[TBL] [Abstract][Full Text] [Related]
12. Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.
Azuma T; Sugihara T; Honda S; Yoshizaki U; Niimi F; Tsuru I; Kume H
Oncol Lett; 2019 Apr; 17(4):4011-4015. PubMed ID: 30881514
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma.
Narukawa T; Hongo F; Fujihara A; Ueno A; Matsugasumi T; Ukimura O
Case Rep Oncol; 2020; 13(1):249-254. PubMed ID: 32308585
[TBL] [Abstract][Full Text] [Related]
14. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
15. A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment.
Yoshida T; Tanaka T; Shindo T; Kyoda Y; Hashimoto K; Kobayashi K; Hasegawa T; Masumori N
Int Cancer Conf J; 2022 Apr; 11(2):134-137. PubMed ID: 35402130
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
17. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
18. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report.
Murata M; Ikeda Y; Hasegawa G; Nakagawa Y; Nishiyama T
J Med Case Rep; 2019 Apr; 13(1):98. PubMed ID: 31006385
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer.
Yasuoka S; Yuasa T; Fujiwara R; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2020 Nov; 40(11):6493-6497. PubMed ID: 33109588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
